Floatz logo

ROSEMARY

Multiple Sclerosis (MS)

University of Oran 1other_biologicalN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

182 Active assets in the Multiple Sclerosis (MS) cohort.

Asset / SponsorPhaseRating
Fampridine
MGH Institute of Health Professions
Phase 4BBB
Teriflunomide
Sanofi
Phase 4BBB
Cladribine
University Hospital, Strasbourg, France
Phase 4BBB
Nabiximols
Jazz Pharmaceuticals
Phase 4BBB
Ocrevus
Polpharma Biologics International AG
Phase 4BBB

View all 50 →

Same molecule, other indications

ROSEMARY is also rated in:

urinary bladder, atony ofDormant
D
Indicative ·
30 / 100
View asset →
overactive bladderDormant
D
Indicative ·
30 / 100
View asset →
Urinary Incontinence (UI)Dormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →